In the past week, KZIA stock has gone up by 39.49%, with a monthly gain of 72.96% and a quarterly surge of 47.79%. The volatility ratio for the week is 25.83%, and the volatility levels for the last 30 days are 12.56% for Kazia Therapeutics Limited ADR. The simple moving average for the past 20 days is 35.63% for KZIA’s stock, with a 65.91% simple moving average for the past 200 days.
Is It Worth Investing in Kazia Therapeutics Limited ADR (NASDAQ: KZIA) Right Now?
Company’s 36-month beta value is 2.12.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KZIA is 23.62M, and currently, short sellers hold a 1.32% ratio of that floaft. The average trading volume of KZIA on October 22, 2024 was 1.47M shares.
KZIA) stock’s latest price update
The stock of Kazia Therapeutics Limited ADR (NASDAQ: KZIA) has increased by 11.78 when compared to last closing price of 0.50.Despite this, the company has seen a gain of 39.49% in its stock price over the last five trading days. prnewswire.com reported 2024-10-02 that Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR) Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably to historical response rates for whole brain radiation therapy alone SYDNEY, Oct. 2, 2024 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation Oncology 66th Annual Meeting (ASTRO 2024), which is taking place from September 29 – October 2, 2024, in Washington, D.C. “The encouraging response rates observed from this Phase 1 study suggests that the concurrent administration of the investigational brain penetrant PI3K inhibitor, paxalisib, in combination radiation therapy appears to be a viable treatment approach for addressing the tumor radioresistance in patients harboring PI3K pathway mutations,” said John Friend, M.D.
Analysts’ Opinion of KZIA
Many brokerage firms have already submitted their reports for KZIA stocks, with Maxim Group repeating the rating for KZIA by listing it as a “Buy.” The predicted price for KZIA in the upcoming period, according to Maxim Group is $18 based on the research report published on October 14, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see KZIA reach a price target of $17. The rating they have provided for KZIA stocks is “Buy” according to the report published on January 05th, 2021.
KZIA Trading at 44.87% from the 50-Day Moving Average
After a stumble in the market that brought KZIA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.46% of loss for the given period.
Volatility was left at 12.56%, however, over the last 30 days, the volatility rate increased by 25.83%, as shares surge +67.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.60% upper at present.
During the last 5 trading sessions, KZIA rose by +39.49%, which changed the moving average for the period of 200-days by +39.70% in comparison to the 20-day moving average, which settled at $0.4141. In addition, Kazia Therapeutics Limited ADR saw 27.78% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for KZIA
Current profitability levels for the company are sitting at:
- -34631.15 for the present operating margin
- 1.0 for the gross margin
The net margin for Kazia Therapeutics Limited ADR stands at -28040.47. The total capital return value is set at -1.49. Equity return is now at value -181.74, with -58.59 for asset returns.
Based on Kazia Therapeutics Limited ADR (KZIA), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -35.3.
Currently, EBITDA for the company is -22.28 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 39111.3. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.71.
Conclusion
In a nutshell, Kazia Therapeutics Limited ADR (KZIA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
